lung cancer

[Scientific Reports] Secondary cisplatin resistance majorly undermines the cisplatin efficacy leading to a worse prognosis. In this respect, researchers identified the role of the DLX6-AS1/miR-181a-5p/miR-382-5p/CELF1 axis in regulating cisplatin resistance of lung squamous cell carcinoma.

[Cell Death & Disease] Scientists evaluated the function of golgi phosphoprotein 3 (GOLPH3) in non-small-cell lung cancer (NSCLC) distal metastasis. GOLPH3 was expressed at high levels in samples from patients with NSCLC and was positively associated with clinicopathologic characteristics including clinical stage classification.

[Scientific Reports] Researchers investigated the role of mTORC1 in regulating translationally controlled tumor protein levels, thereby modulating chemosensitivity, in human lung cancer cells and an A549 lung cancer xenograft model.

[BeyondSpring, Inc.] BeyondSpring announced the first patient has been treated in an investigator-initiated, open-label Phase II study with lead asset plinabulin in combination with nivolumab + ipilimumab in patients with 3rd line recurrent small-cell lung cancer who failed checkpoint inhibitors and platinum-based chemotherapy.

[Theranostics] Lung cancer patient-derived cancer cell and cancer-associated fibroblasts were utilized to mimic the tumor microenvironment and reproduced the stemness properties of cancer stem cells in vitro and developed a high-throughput drug screening platform with phenotypical parameters.

[Nature Communications] Hypothesizing that EGFR mutations alter tumor-immune interactions, scientists compared tumor-infiltrating lymphocytes between EGFR mutant and wild type tumors through single-cell transcriptomic analysis.